ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, usual dosage and administration, relative contraindications, clinically significant drug interactions, adverse drug reactions and overdosage of Nalbuphine. Nalbuphine crosses the placenta rapidly and may achieve fetal blood concentrations approximately equivalent to maternal blood concentrations. Nalbuphine elicits its analgesic, CNS depressant, and respiratory depressant actions primarily by binding to the endorphin receptors in the CNS. Nalbuphine is addicting and habituating. Long-term nalbuphine pharmacotherapy, or regular personal use, may result in addiction and habituation. Concurrent alcohol use may increase the CNS depressant action of nalbuphine. Advise patients to avoid, or limit, their use of alcohol while receiving nalbuphine pharmacotherapy. Signs and symptoms of nalbuphine overdosage are similar to the signs and symptoms associated with other opiate analgesic overdosages, although respiratory depression is reportedly less severe. Nalbuphine overdosage requires emergency symptomatic medical support of body systems with attention to increasing nalbuphine elimination.
